logo
logo

Mingsight Completes A New Round Of Financing To Accelerate Clinical Development In Chronic Lymphocytic Leukemia And Diabetic Macular Edema

Mingsight Completes A New Round Of Financing To Accelerate Clinical Development In Chronic Lymphocytic Leukemia And Diabetic Macular Edema

11/12/21, 1:18 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgsan diego
MingSight Pharmaceuticals announced today the close of a pre-Series B round of $20M, led by Kaitai Capital. The proceeds will be used for the clinical development of MS-553, a new generation inhibitor of protein kinase C (PKC) beta for the treatment of Chronic lymphocytic Leukemia (CLL) and Diabetic Macular Edema (DME).

Company Info

Company
Ming Sight Pharmaceuticals
Location
san diego, california, united states
Additional Info
MingSight is a clinical stage company focused on developing differentiated, novel therapies for serious diseases including B-cell malignancies, diabetic macular edema, and autoimmune diseases. The company is headquartered in San Diego, California, USA.